MacroGenics is a biopharmaceutical company focused on discovering and developing innovative antibody-based therapeutics for the treatment of cancer. Our core scientific expertise is in the field of protein engineering and our pipeline of immuno-oncology product candidates have been created through our proprietary protein engineering platforms, including our DART® bispecific and Fc Optimization technologies. Our product candidates and platforms have attracted multiple partnerships with leading pharmaceutical and biotechnology companies around the globe.